Such adaptations create therapeutic dependencies: VHL-mutant ccRCC exhibit exquisite sensitivity to HIF-2α antagonists [83], whereas IDH1-mutant gliomas succumb to AG-120-mediated 2-hydroxyglutarate depletion [84]. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.